|Unable to view this e-mail? Click here to view in browser.|
Where do you see the studies of bivalent/bispecific antibodies in the future? What are the most specific indicators for future development in the field?
From bispecific antibodies and monoclonal antibodies as therapeutic agents in the past to bispecific antibodies that are said to have enormous potential to improve the therapeutic outlook for patients across the disease spectrum in the present, but what does the future hold?
We will be happy to send you this article .
and we will send you the article
|I am sure that this article will be interesting to you and give you a first glimpse on the topics that will be discussed at the conference Protein & Antibody in February 2015|
If you have any further questions please contact us by calling +49 (0)30 20913 274 or email us at
We have your email address in our database because we received it from your company. If you don’t want to receive emails from us you can unsubscribe here: One Click Unsubscribe.
If you are a resident of Canada: You are receiving this because you opted in or attended a similar event.
We respect your right for privacy .
This email was sent on behalf of IQPC.
IQPC Gesellschaft für Management Konferenzen mbH, Friedrichstraße 94, 10117 Berlin, Germany
Executives: Silke Klaudat, Richard Worden, Michael R. Worden
Business location: Berlin, Amtsgericht Charlottenburg HRB 76720, Ust.IdNr. DE210454451,
IBAN: DE32 3003 0880 0430 0760 19, BIC: TUBDDEDD
[Response: Read Receipt]
www.pharmaceutical-tech.com – a product of Ochre Media Pvt. Ltd.
Ochre Media Pvt Ltd. Media Resource Centre, 2nd Floor, Oxford Plaza, Secunderabad - 500 003, Telangana, India
Tel: +91 40 4961 4567 I Fax: +91 40 4961 4555